{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T08:26:55Z","timestamp":1751012815453,"version":"3.28.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jpba.2024.116491","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:50:56Z","timestamp":1727675456000},"page":"116491","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oxidative stress-induced degradation of Brinzolamide: Isolation and in-depth characterization of unique hydroxylamine and oxime degradation products"],"prefix":"10.1016","volume":"252","author":[{"given":"Mahesh","family":"Ranga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun Kumar","family":"Modini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju","family":"Doddipalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muralidharan","family":"Kaliyaperumal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anandarup","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116491_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.yrtph.2005.12.001","article-title":"A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity","volume":"44","author":"M\u00fcller","year":"2006","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.jpba.2024.116491_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2125.1994.tb05705.x","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH)","volume":"37","author":"Baber","year":"1994","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2024.116491_bib3","unstructured":"Impurities in new drug substances Q3A (R1), testing of new drug substances and products Q3a (R1), in: Proceedings of the International Conference on Harmonization, Geneva, 2002."},{"key":"10.1016\/j.jpba.2024.116491_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10337-016-3149-2","article-title":"Study of forced degradation behaviour of brinzolamide using LC\u2013ESI\u2013Q-TOF and in silico toxicity prediction","volume":"79","author":"Vishnuvardhan","year":"2016","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2024.116491_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25135\/jcm.2311.2949","article-title":"Development and application of RP\u2013HPLC method for estimation and evaluation of stability of brinzolamide in ophthalmic formulation","author":"Patel","year":"2024","journal-title":"J. Chem. Metrol."},{"year":"1999","series-title":"Analytical Profiles of Drug Substances and Excipients","author":"Hall","key":"10.1016\/j.jpba.2024.116491_bib6"},{"key":"10.1016\/j.jpba.2024.116491_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejpb.2022.09.008","article-title":"Mucoadhesive brinzolamide-loaded nanofibers for alternative glaucoma treatment","volume":"180","author":"Cegielska","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2024.116491_bib8","first-page":"706","article-title":"Stability indicating analytical method development and validation of brinzolamide in bulk drugs","volume":"12","author":"Ghodse","year":"2023","journal-title":"WJPR"},{"key":"10.1016\/j.jpba.2024.116491_bib9","first-page":"150","article-title":"Analytical method development and validation of stability indicating RP-HPLC method for estimation of brinzolamide and brimonidine tartrate in an ophthalmic suspension","volume":"6","author":"Patel","year":"2019","journal-title":"IJRAR"},{"key":"10.1016\/j.jpba.2024.116491_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.22270\/jddt.v10i1.3845","article-title":"Analytical method development and validation for the determination of Brinzolamide by RP-HPLC","volume":"10","author":"Tiwari","year":"2020","journal-title":"J. Drug Deliv. Ther."},{"key":"10.1016\/j.jpba.2024.116491_bib11","article-title":"Development and validation of derivative spectrophotometric method for simultaneous estimation of brimonidine tartrate and brinzolamide in combined dosage form","volume":"4","author":"Vijya","year":"2014","journal-title":"Indo Am. J. Pharm. Res."},{"key":"10.1016\/j.jpba.2024.116491_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/separations10010037","volume":"10","author":"Mandour","year":"2023","journal-title":"Separations"},{"key":"10.1016\/j.jpba.2024.116491_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.38111\/ijapb.20200603005","article-title":"Stability indicating RP-HPLC method for simultaneous estimation of brinzolamide and brimonidine in pharmaceutical dosage forms","volume":"6","author":"Sandhya","year":"2020","journal-title":"Int. J. Adv. Pharm. Biotechnol."},{"key":"10.1016\/j.jpba.2024.116491_bib14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.carbpol.2013.06.052","article-title":"Development of inclusion complex of brinzolamide with hydroxypropyl-\u03b2-cyclodextrin","volume":"98","author":"Zhang","year":"2013","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jpba.2024.116491_bib15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/15421406.2020.1743447","article-title":"Effect of the chemical structure on the drug release from brinzolamide based nano eye-drops","volume":"706","author":"Koseki","year":"2020","journal-title":"Mol. Cryst. Liq. Cryst."},{"key":"10.1016\/j.jpba.2024.116491_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/srep44229","article-title":"Creation of nano eye-drops and effective drug delivery to the interior of the eye","volume":"7","author":"Ikuta","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpba.2024.116491_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.56808\/3027-7922.2623","article-title":"Design, development, and characterization of brinzolamide and brimonidine tartrate nanoemulsion for ophthalmic drug delivery","volume":"46","author":"Choradiya","year":"2022","journal-title":"Thai J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116491_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/op9802125","article-title":"Enantioselective synthesis of brinzolamide (AL-4862), a new topical carbonic anhydrase inhibitor. The \u201cDCAT route\u201d to thiophenesulfonamides","volume":"3","author":"Conrow","year":"1999","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jpba.2024.116491_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3111\/200306069078","article-title":"Cost and effectiveness of brinzolamide versus dorzolamide in current practice: an analysis based on the UK-GPRD database","volume":"6","author":"Deschaseaux-Voinet","year":"2003","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jpba.2024.116491_bib20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10717544.2020.1731861","article-title":"Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy","volume":"27","author":"Li","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jpba.2024.116491_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119761","article-title":"In vitro physicochemical characterization and dissolution of brinzolamide ophthalmic suspensions with similar composition","volume":"588","author":"Vo","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116491_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/s43094-020-00068-4","article-title":"Review on analytical studies of some pharmaceutical compounds containing heterocyclic rings: brinzolamide, timolol maleate, flumethasone pivalate, and clioquinol","volume":"6","author":"Mandour","year":"2020","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116491_bib23","article-title":"Recent overviews on the drug delivery aspects and applications of brinzolamide for the management of glaucoma","volume":"6","author":"Sharma","year":"2023","journal-title":"Health Sci. Rev."},{"key":"10.1016\/j.jpba.2024.116491_bib24","unstructured":"Guidelines on photostability testing of new drug substances and products Q1B, in: Proceedings of the International Conference on Harmonization, IFPMA, 1996."},{"key":"10.1016\/j.jpba.2024.116491_bib25","unstructured":"Impurities in new drug substances Q3A (R1), testing of new drug substances and products Q3a (R1), in: Proceedings of the International conference on harmonization, Geneva, 2002."},{"key":"10.1016\/j.jpba.2024.116491_bib26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1021\/cs300212q","article-title":"Developments in the aerobic oxidation of amines","volume":"2","author":"Sch\u00fcmperli","year":"2012","journal-title":"ACS Catal."},{"key":"10.1016\/j.jpba.2024.116491_bib27","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.3390\/molecules27103293","article-title":"N-dealkylation of amines","volume":"27","author":"Najmi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2024.116491_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1021\/acs.joc.5b01740","article-title":"m-CPBA mediated metal free, rapid oxidation of aliphatic amines to oximes","volume":"81","author":"Patil","year":"2016","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.jpba.2024.116491_bib29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tet.2003.10.100","article-title":"Oxidation of secondary amines by molecular oxygen and cyclohexanone monooxygenase","volume":"60","author":"Colonna","year":"2004","journal-title":"Tetrahedron"},{"key":"10.1016\/j.jpba.2024.116491_bib30","first-page":"793","article-title":"Mild catalytic oxidation of secondary and tertiary amines to nitrones and N-oxides with H2O2 mediated by Pt(ii) catalysts","volume":"10","author":"Colladon","year":"2008","journal-title":"Green\u00a0Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524005338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524005338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T17:51:34Z","timestamp":1731520294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524005338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"alternative-id":["S0731708524005338"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116491","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxidative stress-induced degradation of Brinzolamide: Isolation and in-depth characterization of unique hydroxylamine and oxime degradation products","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116491"}}